Cerevel Therapeutics Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021
Cerevel Therapeutics Holdings, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the quarter, the company reported loss from operations of $50,571,000 against $37,702,000 a year ago. Net loss and comprehensive loss was $50,981,000 against $53,208,000 a year ago. Basic and diluted net loss per share was $0.40 against $0.87 a year ago.